New Psoriatic Arthritis Drug Brodalumab by Amgen Remains Efficient After a Year

June 12, 2014 3:41 AM

14 0

A mid-stage clinical trial shows that a new treatment of psoriatic arthritis by Amgen Inc has effectiveness against the disease without any adverse effects.

A biotech drug, brodalumab, was given to the 168-patient in a trial conducted by the partners Amgen and AstraZeneca Plc. It was seen the after 12 weeks that this drug has produced significant improvement.

Read more

To category page